公开(公告)号：JP2011063594A

公开(公告)日：2011-03-31

申请号：JP2010235798

申请日：2010-10-20

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： ALTENBACH ROBERT J ,  BLACK LAWRENCE A ,  CHANG SOU-JEN ,  COWART MARLON D ,  FAGHIH RAMIN ,  GFESSER GREGORY A ,  KU YI-YIN ,  LIU HUAQING ,  LUKIN KIRILL A ,  NERSESIAN DIANA L ,  PU YU-MING ,  SHARMA PADAM N ,  BENNANI YOUSSEF L ,  CURTIS MICHAEL P

IPC: C07C255/58 ,  A61P3/00 ,  A61P25/00 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/20 ,  C07D213/30 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D215/12 ,  C07D215/14 ,  C07D215/20 ,  C07D217/14 ,  C07D237/12 ,  C07D237/14 ,  C07D237/28 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D263/32 ,  C07D277/28 ,  C07D295/073 ,  C07D295/092 ,  C07D295/096 ,  C07D295/112 ,  C07D295/135 ,  C07D295/155 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04

CPC classification number: C07C255/58 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/20 ,  C07D213/30 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D215/12 ,  C07D215/14 ,  C07D215/20 ,  C07D217/14 ,  C07D237/12 ,  C07D237/14 ,  C07D237/28 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D263/32 ,  C07D277/28 ,  C07D295/073 ,  C07D295/088 ,  C07D295/096 ,  C07D295/112 ,  C07D295/135 ,  C07D295/155 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04

Abstract: PROBLEM TO BE SOLVED: To provide pharmaceutical compositions useful in treating conditions or disorders which are prevented or ameliorated by histamine-3 receptor ligands, a method of using such compounds and compositions, and a preparation process therefor.
SOLUTION: There are provided a compound of formula (I), pharmaceutically acceptable salts, esters, amides or prodrugs thereof. Pharmaceutical compositions, usage and preparation process therefor are also provided. In the formula, each symbol is defined specifically.
COPYRIGHT: (C)2011,JPO&INPIT

Abstract translation: 待解决的问题：提供可用于治疗由组胺-3受体配体预防或改善的病症或病症的药物组合物，使用这些化合物和组合物的方法及其制备方法。 解决方案：提供式（I）的化合物，其药学上可接受的盐，酯，酰胺或前药。 还提供了药物组合物，用途和制备方法。 在公式中，每个符号都被具体定义。 版权所有（C）2011，JPO＆INPIT

公开(公告)号：WO0224648A3

公开(公告)日：2002-06-13

申请号：PCT/US0129408

申请日：2001-09-20

Applicant: ABBOTT LAB

Inventor： GUPTA ASHOK K ,  KING STEVEN A ,  LEE ELAINE C ,  MORTON HOWARD E ,  PLATA DANIEL J ,  PU YU-MING ,  SHARMA PADAM N

IPC: C07D209/08

CPC classification number: C07D209/08

Abstract: The instant invention discloses a process for the synthesis of substituted indole cell proliferation inhibitors, comprising the reaction of 1-formyl indoline with clorosulfonic acid and thionyl chloride, followed by reaction with an aromatic amine.

Abstract translation: 本发明公开了一种合成取代的吲哚细胞增殖抑制剂的方法，其包括1-甲酰基二氢吲哚与氯磺酸和亚硫酰氯的反应，然后与芳族胺反应。

公开(公告)号：WO2004076388A2

公开(公告)日：2004-09-10

申请号：PCT/US2004005573

申请日：2004-02-25

Applicant: ABBOTT LAB

Inventor： KU YI-YIN ,  COWART MARLON D ,  SHARMA PADAM N

IPC: C07D207/08 ,  C07D295/02 ,  C07D295/027 ,  C07D295/185 ,  C07C

CPC classification number: C07D207/08 ,  C07D295/027 ,  C07D295/185

Abstract: The invention relates to a process for preparing 2-methylpyrrolidine and, more particularly, specific enantiomers of 2-methylpyrrolidine. Novel intermediates also are described.

Abstract translation: 本发明涉及一种制备2-甲基吡咯烷的方法，更具体地说，涉及2-甲基吡咯烷的特定对映异构体。 还描述了新的中间体。

公开(公告)号：AU2003291329A1

公开(公告)日：2004-06-03

申请号：AU2003291329

申请日：2003-11-05

Applicant: ABBOTT LAB

Inventor： FAGHIH RAMIN ,  GFESSER GREGORY A ,  KU YI-YIN ,  LIU HUAQING ,  LUKIN KIRILL A ,  NERSESIAN DIANA L ,  PU YU-MING ,  SHARMA PADAM N ,  BENNANI YOUSSEF L ,  CURTIS MICHAEL P ,  ALTENBACH ROBERT J ,  BLACK LAWRENCE A ,  CHANG SOU-JEN ,  COWART MARLON D

IPC: A61P3/00 ,  A61P25/00 ,  C07C255/58 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/20 ,  C07D213/30 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D215/12 ,  C07D215/14 ,  C07D215/20 ,  C07D217/14 ,  C07D237/12 ,  C07D237/14 ,  C07D237/28 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D263/32 ,  C07D277/28 ,  C07D295/073 ,  C07D295/092 ,  C07D295/096 ,  C07D295/112 ,  C07D295/135 ,  C07D295/155 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  A61K31/40 ,  C07D261/08 ,  C07D295/088 ,  C07D295/116

公开(公告)号：CA2505427A1

公开(公告)日：2004-05-27

申请号：CA2505427

申请日：2003-11-05

Applicant: ABBOTT LAB

Inventor： LIU HUAQING ,  LUKIN KIRILL A ,  NERSESIAN DIANA L ,  PU YU-MING ,  SHARMA PADAM N ,  BLACK LAWRENCE A ,  BENNANI YOUSSEF L ,  CHANG SOU-JEN ,  CURTIS MICHAEL P ,  ALTENBACH ROBERT J ,  COWART MARLON D ,  GFESSER GREGORY A ,  FAGHIH RAMIN ,  KU YI-YIN

IPC: A61P3/00 ,  A61P25/00 ,  C07C255/58 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/20 ,  C07D213/30 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D215/12 ,  C07D215/14 ,  C07D215/20 ,  C07D217/14 ,  C07D237/12 ,  C07D237/14 ,  C07D237/28 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D263/32 ,  C07D277/28 ,  C07D295/073 ,  C07D295/092 ,  C07D295/096 ,  C07D295/112 ,  C07D295/135 ,  C07D295/155 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  A61K31/40 ,  C07D261/08 ,  C07D295/088 ,  C07D295/116

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for prepari ng compounds within the scope of formula (I).

公开(公告)号：DK0968189T3

公开(公告)日：2002-02-18

申请号：DK98906497

申请日：1998-02-18

Applicant: ABBOTT LAB

Inventor： SHARMA PADAM N ,  VANDREVALA MARAZBAN H

IPC: C07D213/803 ,  C07D213/80 ,  C07D213/82 ,  C07B41/08

Abstract: The present invention relates to an improved process for the preparation of nicotinic acids represented by the following structural formula (I): I which are prepared by reacting a nicotinic amide compound having the formula: under acidic conditions with a nitrite salt. In the process of the invention have the groups R1, R2, and R3, in the compounds are independently selected from the group consisting of hydrogen, and halogen atoms and R4 is selected from the group consisting of hydrogen, lower alkyl and aryl. The process provides the nicotinic acid compounds in improved yields.

公开(公告)号：AT208378T

公开(公告)日：2001-11-15

申请号：AT98906497

申请日：1998-02-18

Applicant: ABBOTT LAB

Inventor： SHARMA PADAM N ,  VANDREVALA MARAZBAN H

IPC: C07D213/803 ,  C07D213/80 ,  C07D213/82 ,  C07B41/08

Abstract: The present invention relates to an improved process for the preparation of nicotinic acids represented by the following structural formula (I): I which are prepared by reacting a nicotinic amide compound having the formula: under acidic conditions with a nitrite salt. In the process of the invention have the groups R1, R2, and R3, in the compounds are independently selected from the group consisting of hydrogen, and halogen atoms and R4 is selected from the group consisting of hydrogen, lower alkyl and aryl. The process provides the nicotinic acid compounds in improved yields.

公开(公告)号：AU737619B2

公开(公告)日：2001-08-23

申请号：AU6170798

申请日：1998-02-18

Applicant: ABBOTT LAB

Inventor： SHARMA PADAM N ,  VANDREVALA MARAZBAN H

IPC: C07D213/803 ,  C07D213/80 ,  C07D213/82 ,  C07B41/08

Abstract: The present invention relates to an improved process for the preparation of nicotinic acids represented by the following structural formula (I): I which are prepared by reacting a nicotinic amide compound having the formula: under acidic conditions with a nitrite salt. In the process of the invention have the groups R1, R2, and R3, in the compounds are independently selected from the group consisting of hydrogen, and halogen atoms and R4 is selected from the group consisting of hydrogen, lower alkyl and aryl. The process provides the nicotinic acid compounds in improved yields.

公开(公告)号：CA2282381A1

公开(公告)日：1998-09-11

申请号：CA2282381

申请日：1998-02-18

Applicant: ABBOTT LAB

Inventor： SHARMA PADAM N ,  VANDREVALA MARAZBAN H

IPC: C07D213/803 ,  C07D213/80 ,  C07D213/82 ,  C07B41/08

Abstract: The present invention relates to an improved process for the preparation of nicotinic acids represented by structural formula (I) which are prepared by reacting a nicotinic amide compound having formula (a) under acidic conditions with a nitrite salt. In the process of the invention the groups R1, R2, and R3, in the compounds are independently selected from the group consisting of hydrogen and halogen atoms, and R4 is selected from the group consisting of hydrogen, lower alkyl and aryl. The process provides the nicotinic acid compounds in improved yields.

公开(公告)号：CA2505427C

公开(公告)日：2012-04-03

申请号：CA2505427

申请日：2003-11-05

Applicant: ABBOTT LAB

Inventor： ALTENBACH ROBERT J ,  BLACK LAWRENCE A ,  CHANG SOU-JEN ,  COWART MARLON D ,  FAGHIH RAMIN ,  GFESSER GREGORY A ,  KU YI-YIN ,  LIU HUAQING ,  LUKIN KIRILL A ,  NERSESIAN DIANA L ,  PU YU-MING ,  SHARMA PADAM N ,  BENNANI YOUSSEF L ,  CURTIS MICHAEL P

IPC: C07D471/04 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/445 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/541 ,  A61P3/00 ,  A61P25/00 ,  C07C255/58 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/20 ,  C07D213/30 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D215/12 ,  C07D215/14 ,  C07D215/20 ,  C07D217/14 ,  C07D237/12 ,  C07D237/14 ,  C07D237/28 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D263/32 ,  C07D277/28 ,  C07D295/073 ,  C07D295/092 ,  C07D295/096 ,  C07D295/112 ,  C07D295/135 ,  C07D295/155 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).